We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Clorox (CLX) Q1 Earnings and Sales Top Estimates, Decline Y/Y
Read MoreHide Full Article
The Clorox Company (CLX - Free Report) reported mixed results for first-quarter fiscal 2022, wherein the top and bottom lines beat the Zacks Consensus Estimate but declined year over year. Results were impacted by soft sales performance across two of the four segments. Lower shipment volume along with an unfavorable price mix mainly hurt sales. This along with higher manufacturing and logistics costs, and increased commodity costs dented the bottom line and margins.
Nonetheless, management is encouraged by the company’s portfolio, which helps it efficiently cater to the consumer demand and position it well for long-term growth. Its IGNITE strategy also appears encouraging.
Shares of the Zacks Rank #5 (Strong Sell) company have declined 0.4% in the past three months compared with the industry’s 2.8% fall.
Image Source: Zacks Investment Research
Q1 Highlights
Adjusted earnings of $1.21 per share decreased 54% year over year but beat the Zacks Consensus Estimate of $1.01. The earnings decline can be attributed to a decrease in sales and a lower gross margin. Adjusted earnings excluded 7 cents related to investments in the company's long-term digital capabilities and productivity enhancements.
The company posted net sales of $1,806 million, beating the Zacks Consensus Estimate of $1,703 million. The top line, however, declined 6% from the year-ago quarter, whereas organic sales dipped 5%. Sales were mainly impacted by the decline of volume and unfavorable price mix. The adverse currency also hurt the top line by 1%. The company witnessed a 2% decline in volume and a 3% unfavorable price mix. However, it noted that sales increased 21% on a two-year basis.
The Clorox Company Price, Consensus and EPS Surprise
The gross margin contracted 1,090 basis points (bps) to 37% in the fiscal first quarter. Elevated manufacturing and logistics costs and higher commodity costs due to significant cost inflation hurt the gross margin.
Segmental Discussion
Sales of the Health and Wellness segment dropped 8% to $745 million on sales declines in two of the three business units. Lower shipment volume of professional products; vitamins, minerals and supplements; and unfavorable price mix led to the downside.
The Household segment’s sales declined 12% to $442 million, driven by sales declines in two of the three business units — Bags & Wraps, and Grilling. Unfavorable price mix; lower shipments in Grilling and Bags & Wraps; and unfavorable price mix were the primary reasons.
Sales at the Lifestyle segment improved 4% year over year to $331 million. Growth in two of the three businesses due to higher volume from increased shipments Water Filtration and Natural Personal Care aided the segment’s sales. This was partly negated by the unfavorable price mix.
In the International segment, sales rose 1% to $288 million from the year-ago quarter on a favorable price mix, offset by a slight decline in shipment volume and unfavorable currency. Organic sales for the segment improved 3%.
Financials
Clorox ended first-quarter fiscal 2022 with cash and cash equivalents of $210 million, and long-term debt of $1,885 million. In the fiscal first quarter, the company generated $41 million of net cash from operations.
Fiscal 2022 Guidance
Management notes that fiscal 2022 started on a strong note. It witnessed a better-than-anticipated demand across its portfolio despite the tough environment. The company reiterated its fiscal 2022 outlook. It envisions a 2-6% sales decline, both on a reported and organic basis, for fiscal 2022.
The gross margin is expected to decline 300-400 bps in fiscal 2022 on escalated commodity costs, and manufacturing and logistics expenses, particularly transportation. The company expects to return to gross margin growth in the fourth quarter of fiscal 2022.
Selling and administrative expenses, as a percentage of sales, are projected to be 15% of sales. The company anticipates 1% of this to be for planned investments in digital capabilities and productivity enhancements. It expects advertising and sales promotion expenses to be 10% of net sales. The higher spending mainly relates to an increase in brand investments to support its innovation pipeline and customer engagement efforts. The effective tax rate is anticipated at 22-23%.
Consequently, adjusted earnings for fiscal 2022 are estimated to be $5.40-$5.70 per share, suggesting a year-over-year decline of 26-21%. On a GAAP basis, earnings per share are anticipated to be $5.05-$5.35, indicating a 9-4% decline from the year-ago period. The company notes that adjusted earnings per share will exclude long-term investments in digital capabilities and productivity enhancements to provide greater visibility to the underlying operating performance.
Image: Bigstock
Clorox (CLX) Q1 Earnings and Sales Top Estimates, Decline Y/Y
The Clorox Company (CLX - Free Report) reported mixed results for first-quarter fiscal 2022, wherein the top and bottom lines beat the Zacks Consensus Estimate but declined year over year. Results were impacted by soft sales performance across two of the four segments. Lower shipment volume along with an unfavorable price mix mainly hurt sales. This along with higher manufacturing and logistics costs, and increased commodity costs dented the bottom line and margins.
Nonetheless, management is encouraged by the company’s portfolio, which helps it efficiently cater to the consumer demand and position it well for long-term growth. Its IGNITE strategy also appears encouraging.
Shares of the Zacks Rank #5 (Strong Sell) company have declined 0.4% in the past three months compared with the industry’s 2.8% fall.
Q1 Highlights
Adjusted earnings of $1.21 per share decreased 54% year over year but beat the Zacks Consensus Estimate of $1.01. The earnings decline can be attributed to a decrease in sales and a lower gross margin. Adjusted earnings excluded 7 cents related to investments in the company's long-term digital capabilities and productivity enhancements.
The company posted net sales of $1,806 million, beating the Zacks Consensus Estimate of $1,703 million. The top line, however, declined 6% from the year-ago quarter, whereas organic sales dipped 5%. Sales were mainly impacted by the decline of volume and unfavorable price mix. The adverse currency also hurt the top line by 1%. The company witnessed a 2% decline in volume and a 3% unfavorable price mix. However, it noted that sales increased 21% on a two-year basis.
The Clorox Company Price, Consensus and EPS Surprise
The Clorox Company price-consensus-eps-surprise-chart | The Clorox Company Quote
The gross margin contracted 1,090 basis points (bps) to 37% in the fiscal first quarter. Elevated manufacturing and logistics costs and higher commodity costs due to significant cost inflation hurt the gross margin.
Segmental Discussion
Sales of the Health and Wellness segment dropped 8% to $745 million on sales declines in two of the three business units. Lower shipment volume of professional products; vitamins, minerals and supplements; and unfavorable price mix led to the downside.
The Household segment’s sales declined 12% to $442 million, driven by sales declines in two of the three business units — Bags & Wraps, and Grilling. Unfavorable price mix; lower shipments in Grilling and Bags & Wraps; and unfavorable price mix were the primary reasons.
Sales at the Lifestyle segment improved 4% year over year to $331 million. Growth in two of the three businesses due to higher volume from increased shipments Water Filtration and Natural Personal Care aided the segment’s sales. This was partly negated by the unfavorable price mix.
In the International segment, sales rose 1% to $288 million from the year-ago quarter on a favorable price mix, offset by a slight decline in shipment volume and unfavorable currency. Organic sales for the segment improved 3%.
Financials
Clorox ended first-quarter fiscal 2022 with cash and cash equivalents of $210 million, and long-term debt of $1,885 million. In the fiscal first quarter, the company generated $41 million of net cash from operations.
Fiscal 2022 Guidance
Management notes that fiscal 2022 started on a strong note. It witnessed a better-than-anticipated demand across its portfolio despite the tough environment. The company reiterated its fiscal 2022 outlook. It envisions a 2-6% sales decline, both on a reported and organic basis, for fiscal 2022.
The gross margin is expected to decline 300-400 bps in fiscal 2022 on escalated commodity costs, and manufacturing and logistics expenses, particularly transportation. The company expects to return to gross margin growth in the fourth quarter of fiscal 2022.
Selling and administrative expenses, as a percentage of sales, are projected to be 15% of sales. The company anticipates 1% of this to be for planned investments in digital capabilities and productivity enhancements. It expects advertising and sales promotion expenses to be 10% of net sales. The higher spending mainly relates to an increase in brand investments to support its innovation pipeline and customer engagement efforts. The effective tax rate is anticipated at 22-23%.
Consequently, adjusted earnings for fiscal 2022 are estimated to be $5.40-$5.70 per share, suggesting a year-over-year decline of 26-21%. On a GAAP basis, earnings per share are anticipated to be $5.05-$5.35, indicating a 9-4% decline from the year-ago period. The company notes that adjusted earnings per share will exclude long-term investments in digital capabilities and productivity enhancements to provide greater visibility to the underlying operating performance.
Key Stocks to Consider
Albertsons Companies, Inc. (ACI - Free Report) has an expected long-term earnings growth rate of 12% and it currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
The Duckhorn Portfolio (NAPA - Free Report) has an expected long-term earnings growth rate of 9.4% and a Zacks Rank #2 (Buy) at present.
Helen of Troy (HELE - Free Report) , also a Zacks Rank #2 stock, has an expected long-term earnings growth rate of 8%.